Identification of eight candidate target genes of the recurrent 3p12-p14 loss in cervical cancer by integrative genomic profiling

Journal of Pathology

Volumn 230, Issue 1, 2013, Pages 59-69

  Lando, Malin ^a   Wilting, Saskia M ^b   Snipstad, Kristin ^a,c   Clancy, Trevor ^a   Bierkens, Mariska ^b   Aarnes, Eva Katrine ^a   Holden, Marit ^d   Stokke, Trond ^a   Sundfør, Kolbein ^a   Holm, Ruth ^a   Kristensen, Gunnar B ^a,e   Steenbergen, Renske D M ^b   Lyng, Heidi ^a  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^c UNIVERSITY OF TROMSØ   (Norway)

^d NORWEGIAN COMPUTING CENTER   (Norway)

^e UNIVERSITY OF OSLO   (Norway)

Author keywords

array CGH; carcinogenesis; cervical cancer; cervical intraepithelial neoplasia; chromosome 3p; gene expression; genetic loss; integrative genomic profiling; target genes; tumour suppressor genes

Indexed keywords

APOPTOSIS; ARTICLE; CANCER GRADING; CANCER INVASION; CANCER RECURRENCE; CARCINOGENESIS; CELL PROLIFERATION; CHROMOSOME 3P; COPY NUMBER VARIATION; DOWN REGULATION; EBLN2 GENE; GBE1 GENE; GENE; GENE ACTIVATION; GENE EXPRESSION; GENE IDENTIFICATION; GENE LOSS; GENE TARGETING; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; PRIORITY JOURNAL; PSMD6 GENE; SHQ1 GENE; SLC25A26 GENE; STRESS; THOC7 GENE; TMF1 GENE; TUMOR GENE; UTERINE CERVIX CANCER; VALIDATION STUDY;

AMINO ACID TRANSPORT SYSTEMS; APOPTOSIS; CALCIUM-BINDING PROTEINS; CARCINOMA, SQUAMOUS CELL; CARRIER PROTEINS; CHROMOSOMES, HUMAN, PAIR 3; DNA-BINDING PROTEINS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, TUMOR SUPPRESSOR; GLYCOGEN DEBRANCHING ENZYME SYSTEM; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; PROGNOSIS; PROTEASOME ENDOPEPTIDASE COMPLEX; RNA, SMALL INTERFERING; RNA-BINDING PROTEINS; TRANSCRIPTION FACTORS; TRANSCRIPTOME; UTERINE CERVICAL NEOPLASMS;

EID: 84876122536     PISSN: 00223417     EISSN: 10969896     Source Type: Journal    
DOI: 10.1002/path.4168     Document Type: Article

References (44)

1. Pett M, Coleman N,. Integration of high-risk human papillomavirus: a key event in cervical carcinogenesis? J Pathol 2007; 212: 356-367.
2. Snijders PJ, Steenbergen RD, Heideman DA, et al,. HPV-mediated cervical carcinogenesis: concepts and clinical implications. J Pathol 2006; 208: 152-164.
3. Bierkens M, Wilting SM, van Wieringen WN, et al,. Chromosomal profiles of high-grade cervical intraepithelial neoplasia relate to duration of preceding high-risk human papillomavirus infection. Int J Cancer 2012; 131: E579-E585.
4. Bierkens M, Wilting SM, van Wieringen WN, et al,. HPV type-related chromosomal profiles in high-grade cervical intraepithelial neoplasia. BMC Cancer 2012; 12: 36.
5. Wilting SM, Steenbergen RD, Tijssen M, et al,. Chromosomal signatures of a subset of high-grade premalignant cervical lesions closely resemble invasive carcinomas. Cancer Res 2009; 69: 647-655.
6. Heselmeyer K, Macville M, Schrock E, et al,. Advanced-stage cervical carcinomas are defined by a recurrent pattern of chromosomal aberrations revealing high genetic instability and a consistent gain of chromosome arm 3q. Genes Chromosomes Cancer 1997; 19: 233-240.
7. Lando M, Holden M, Bergersen LC, et al,. Gene dosage, expression, and ontology analysis identifies driver genes in the carcinogenesis and chemoradioresistance of cervical cancer. PLoS Genet 2009; 5: e1000719.
8. Kok K, Naylor SL, Buys CH,. Deletions of the short arm of chromosome 3 in solid tumors and the search for suppressor genes. Adv Cancer Res 1997; 71: 27-92.
9. Birch AH, Quinn MC, Filali-Mouhim A, et al,. Transcriptome analysis of serous ovarian cancers identifies differentially expressed chromosome 3 genes. Mol Carcinog 2008; 47: 56-65.
10. Taylor BS, Schultz N, Hieronymus H, et al,. Integrative genomic profiling of human prostate cancer. Cancer Cell 2010; 18: 11-22.
11. Zabarovsky ER, Lerman MI, Minna JD,. Tumor suppressor genes on chromosome 3p involved in the pathogenesis of lung and other cancers. Oncogene 2002; 21: 6915-6935.
12. Bignell GR, Greenman CD, Davies H, et al,. Signatures of mutation and selection in the cancer genome. Nature 2010; 463: 893-898.
13. Harden SV, Guo Z, Epstein JI, et al,. Quantitative GSTP1 methylation clearly distinguishes benign prostatic tissue and limited prostate adenocarcinoma. J Urol 2003; 169: 1138-1142.
14. Lockwood WW, Coe BP, Williams AC, et al,. Whole genome tiling path array CGH analysis of segmental copy number alterations in cervical cancer cell lines. Int J Cancer 2007; 120: 436-443.
15. Vindelov LL, Christensen IJ, Nissen NI,. A detergent-trypsin method for the preparation of nuclei for flow cytometric DNA analysis. Cytometry 1983; 3: 323-327.
16. Razick S, Magklaras G, Donaldson IM,. iRefIndex: a consolidated protein interaction database with provenance. BMC Bioinformatics 2008; 9: 405.
17. Smyth GK. Linear models and empirical Bayes methods for assessing differential expression in microarray experiments. Stat Appl Genet Mol Biol 2004; 3: Article 3.
18. Dinu I, Potter JD, Mueller T, et al,. Improving gene set analysis of microarray data by SAM-GS. BMC Bioinformatics 2007; 8: 242.
19. Liu Q, Dinu I, Adewale AJ, et al,. Comparative evaluation of gene-set analysis methods. BMC Bioinformatics 2007; 8: 431.
20. Benjamini Y, Hochberg Y,. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc B 1995; 57: 289-300.
21. Mootha VK, Lindgren CM, Eriksson KF, et al,. PGC-1α-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes. Nature Genet 2003; 34: 267-273.
22. Shannon P, Markiel A, Ozier O, et al,. Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome Res 2003; 13: 2498-2504.
23. Beisvag V, Junge FK, Bergum H, et al,. GeneTools-application for functional annotation and statistical hypothesis testing. BMC Bioinformatics 2006; 7: 470.
24. Chi JT, Wang Z, Nuyten DS, et al,. Gene expression programs in response to hypoxia: cell type specificity and prognostic significance in human cancers. PLoS Med 2006; 3: e47.
25. Wistuba II, Montellano FD, Milchgrub S, et al,. Deletions of chromosome 3p are frequent and early events in the pathogenesis of uterine cervical carcinoma. Cancer Res 1997; 57: 3154-3158.
26. Dasgupta S, Chakraborty SB, Roy A, et al,. Differential deletions of chromosome 3p are associated with the development of uterine cervical carcinoma in Indian patients. Mol Pathol 2003; 56: 263-269.
27. Lyng H, Beigi M, Svendsrud DH, et al,. Intratumor chromosomal heterogeneity in advanced carcinomas of the uterine cervix. Int J Cancer 2004; 111: 358-366.
28. Ji L, Roth JA,. Tumor suppressor FUS1 signaling pathway. J Thorac Oncol 2008; 3: 327-330.
29. Tian X, Liu Z, Niu B, et al,. E-cadherin/beta-catenin complex and the epithelial barrier. J Biomed Biotechnol 2011; 2011: 567305.
30. Melchor L, Saucedo-Cuevas LP, Munoz-Repeto I, et al,. Comprehensive characterization of the DNA amplification at 13q34 in human breast cancer reveals TFDP1 and CUL4A as likely candidate target genes. Breast Cancer Res 2009; 11: R86.
31. Cheng Y, Zhou Y, Jiang W, et al,. Significance of E-cadherin, beta-catenin, and vimentin expression as postoperative prognosis indicators in cervical squamous cell carcinoma. Hum Pathol 2012; 43: 1213-1220.
32. Zheng L, Schickling O, Peter ME, et al,. The death effector domain-associated factor plays distinct regulatory roles in the nucleus and cytoplasm. J Biol Chem 2001; 276: 31945-31952.
33. Abrham G, Volpe M, Shpungin S, et al,. TMF/ARA160 downregulates proangiogenic genes and attenuates the progression of PC3 xenografts. Int J Cancer 2009; 125: 43-53.
34. Frankland-Searby S, Bhaumik SR,. The 26S proteasome complex: an attractive target for cancer therapy. Biochim Biophys Acta 2012; 1825: 64-76.
35. Nallar SC, Lin L, Srivastava V, et al,. GRIM-1, a novel growth suppressor, inhibits rRNA maturation by suppressing small nucleolar RNAs. PLoS One 2011; 6: e24082.
36. El Bounkari O, Guria A, Klebba-Faerber S, et al. Nuclear localization of the pre-mRNA associating protein THOC7 depends upon its direct interaction with Fms tyrosine kinase interacting protein (FMIP). FEBS Lett 2009; 583: 13-18.
37. del Arco A, Satrustegui J,. Identification of a novel human subfamily of mitochondrial carriers with calcium-binding domains. J Biol Chem 2004; 279: 24701-24713.
38. Albertson DG, Collins C, McCormick F, et al,. Chromosome aberrations in solid tumors. Nature Genet 2003; 34: 369-376.
39. Bulkmans NW, Berkhof J, Rozendaal L, et al,. Human papillomavirus DNA testing for the detection of cervical intraepithelial neoplasia grade 3 and cancer: 5-year follow-up of a randomised controlled implementation trial. Lancet 2007; 370: 1764-1772.
40. Lyng H, Brovig RS, Svendsrud DH, et al,. Gene expressions and copy numbers associated with metastatic phenotypes of uterine cervical cancer. BMC Genomics 2006; 7: 268.
41. Buffart TE, Tijssen M, Krugers T, et al,. DNA quality assessment for array CGH by isothermal whole genome amplification. Cell Oncol 2007; 29: 351-359.
42. van de Wiel MA, Kim KI, Vosse SJ, et al,. CGHcall: calling aberrations for array CGH tumor profiles. Bioinformatics 2007; 23: 892-894.
43. Hupe P, Stransky N, Thiery JP, et al,. Analysis of array CGH data: from signal ratio to gain and loss of DNA regions. Bioinformatics 2004; 20: 3413-3422.
44. Lyng H, Lando M, Brovig RS, et al,. GeneCount: genome-wide calculation of absolute tumor DNA copy numbers from array comparative genomic hybridization data. Genome Biol 2008; 9: R86.